Company profile
CAMP4 Therapeutics Corporation
NASDAQ: CAMP · Healthcare · Biotechnology
#735 of 1,418 Healthcare companies by revenuetop-decile growth
EA Score
27DFH 32DQ 15GM —SS 40
v0.1 · 55/100 weight · provisional
↑ revenue growth (YoY), market scale · ↓ listing tenure, disclosure history
Methodology →Revenue TTM
$3.9M
Rev growth YoY (TTM)
+160.5%
Net income (FY)
-$80.4M
Employees
48
as of 2026-08-18
Market cap
$105.5M
as of 2026-08-18
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$3.5M$3.5M2025
Net income-$80.4M-$80.4M2025
Operating income-$52.6M-$52.6M2025
Total assets$117.8M$117.8M2025
Liabilities$70.1M$70.1M2025
Equity$47.7M$47.7M2025
Revenue trend
FY2024 – FY2025 · USD
FY24
FY24
FY25
Revenue by segment
Filed disclosures · FY2022
By product
Product64%
Application Subscriptions And Other Services36%
By geography
UNITED STATES63%
EMEA19%
Latin America11%
Asia Pacific6%
All Other1%
The read
What is CAMP4 Therapeutics Corporation’s revenue?
CAMP4 Therapeutics Corporation booked $3.5M in FY2025 revenue, growing 437% year over year — faster than 93% of Healthcare companies we track, at a -2298.5% net margin.
Peers · Healthcare
Marker Therapeutics, Inc.36DRevitalist Lifestyle and Wellness Ltd.——SheerVision, Inc.——Surrozen, Inc.30DTelescope Innovations Corp.——Caliber Imaging & Diagnostics, Inc.——Neighbors
Middlesex →Key facts
CEOJoshua Mandel-Brehm
SectorHealthcare
IndustryBiotechnology
HeadquartersCambridge, MA
ExchangeNASDAQ: CAMP
Employees48
IPO date2024-10-11
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.